Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 17/20 | 1.00 |
| ▸ | CTSD | P07339 | 2/20 | 0.84 |
| ▸ | APP | P05067 | 8/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGAV | P06756 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021454 | 0.92 | BACE1 (0.84) | BACE1CTSDAPP | |
| SCHEMBL3013661 | 0.92 | BACE1 (1.00) | BACE1CTSDAPPALDH1A1HPGD | |
| SCHEMBL3014975 | 0.90 | BACE1 (1.00) | BACE1CTSDAPP | |
| SCHEMBL3020820 | 0.86 | BACE1 (1.00) | BACE1CTSDAPPALDH1A1CYP1A2 | |
| SCHEMBL3014874 | 0.86 | BACE1 (1.00) | BACE1CTSDAPP | |
| SCHEMBL3017322 | 0.83 | BACE1 (1.00) | BACE1CTSDAPP | |
| SCHEMBL3016243 | 0.83 | BACE1 (0.70) | BACE1CTSDAPPALDH1A1TP53 | |
| SCHEMBL3008359 | 0.81 | BACE1 (1.00) | BACE1CTSDAPP | |
| SCHEMBL3021899 | 0.81 | BACE1 (0.68) | BACE1CTSDAPPALDH1A1HPGD | |
| SCHEMBL3018386 | 0.81 | BACE1 (1.00) | BACE1CTSDAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204245-A1 | Amino-pyridines As Inhibitors Of Beta-secretase | WYETH LLC (US) | 2010-08-12 | — | — | US | claimed |
| US-20060173049-A1 | enzyme inhibitors such as 6-{2-(2-Chloro-phenyl)-5-[4-(pyrimidin-2-yloxy)-phenyl]pyrrol-1-ylmethyl}-pyridin-2-ylamine, used to treat beta-amyloid deposits and neurofibrillary tangles; Alzheimer's disease | WYETH (US) | 2006-08-03 | — | — | US | claimed |
| US-20100204245-A1 | Amino-pyridines As Inhibitors Of Beta-secretase | WYETH LLC (US) | 2010-08-12 | — | — | US | disclosed |
| US-7732457-B2 | Amino-pyridines as inhibitors of β-secretase | WYETH LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-20060173049-A1 | enzyme inhibitors such as 6-{2-(2-Chloro-phenyl)-5-[4-(pyrimidin-2-yloxy)-phenyl]pyrrol-1-ylmethyl}-pyridin-2-ylamine, used to treat beta-amyloid deposits and neurofibrillary tangles; Alzheimer's disease | WYETH (US) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204245-A1 | Amino-pyridines As Inhibitors Of Beta-secretase | BACE1, BACE2, APP | BACE1 1/4885CTSD 205/4885APP 3/4885 |
| US-20060173049-A1 | enzyme inhibitors such as 6-{2-(2-Chloro-phenyl)-5-[4-(pyrimidin-2-yloxy)-phenyl]pyrrol-1-ylmethyl}-pyridin-2-ylamine, used to treat beta-amyloid deposits and neurofibrillary tangles; Alzheimer's disease | BACE1, BACE2, PSEN1 | BACE1 1/4885CTSD 126/4885APP 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.